Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency

Maria Carmina Castiello, PhD,a,b* Marita Bosticardo, PhD,c* Niccolò Sacchetti, PhD,a Enrica Calzoni, MD,a,c Elena Fontana, PhD,d,e Yasuhiro Yamazaki, MD, PhD,f Elena Draghici, BS,f Cristiana Corsino,f Ileana Bortolomai, PhD,a Lucia Sereni, PhD,a Hsin-Hui Yu, MD, PhD,f Paolo Uva, PhD,f Rahul Palchaudhuri, PhD,f,g,h David T. Scadden, MD,f,g Anna Villa, MD,a,b and Luigi D. Notarangelo, MDb Milan and Pula, Cagliari, Italy; Bethesda, Md; and Cambridge and Boston, Mass

GRAPHICAL ABSTRACT

CD45-SAP is a safe and efficacious conditioning in RAG1 deficiency

HSC chimerism* <5% 10% 60% 90%
T cell reconstitution absent poor full full
B cell reconstitution absent poor full full
Antibody response absent poor present present

* Average values between the two mouse models. HSCT, Hematopoietic Stem Cell Transplantation; SCID, Severe Combined Immunodeficiency; CID, Combined Immunodeficiency; CD45-SAP, anti-CD45-Saporin; TBI, Total Body Irradiation.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication January 28, 2020; revised April 8, 2020; accepted for publication April 10, 2020.

Available online May 6, 2020.

Corresponding author: Anna Villa, MD, SR-Tiget, Via Olgettina 58, Milan, 20127, Italy. E-mail: villa.anna@hsr.it. Or: Luigi D. Notarangelo, MD, Immune Deficiency Genetics Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Building 10, Room 5-3950, 10 Center Drive, Bethesda, MD 20892. E-mail: luigi.notarangelo2@nih.gov.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections.

0091-6749 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jaci.2020.04.033
Background: Mutations in the recombinase-activating genes cause severe immunodeficiency, with a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation. Hematopoietic stem cell transplantation is the only curative option, but a high risk of graft failure and poor immune reconstitution have been observed in the absence of myeloablation. Objectives: Our aim was to improve multilineage engraftment; we tested nongenotoxic conditioning with anti-CD45 mAbs conjugated with saporin CD45 (CD45-SAP).

Methods: Rag1-KO and Rag1-F971L mice, which represent models of severe combined immune deficiency and combined immune deficiency with immune dysregulation, respectively, were conditioned with CD45-SAP, CD45-SAP plus 2 Gy of total body irradiation (TBI), 2 Gy of TBI, 8 Gy of TBI, or no conditioning and treated by using transplantation with lineage-negative bone marrow cells from wild-type mice. Flow cytometry and immunohistochemistry were used to assess engraftment and immune reconstitution. Antibody responses to 2,4,6-trinitrophenyl–conjugated keyhole limpet hemocyanin were measured by ELISA, and presence of autoantibody was assessed by microarray.

Results: Conditioning with CD45-SAP enabled high levels of multilineage engraftment in both Rag1 mutant models, allowed overcoming of B- and T-cell differentiation blocks and thymic epithelial cell defects, and induced robust cellular and humoral immunity in the periphery.

Conclusions: Conditioning with CD45-SAP allows multilineage engraftment and robust immune reconstitution in mice with either null or hypomorphic Rag mutations while preserving thymic epithelial cell homeostasis. (J Allergy Clin Immunol 2021;147:309-20.)

**Key words:** RAG deficiency, conditioning, anti-CD45–saporin, immunotoxin, engraftment, immune reconstitution, hematopoietic stem cell transplantation, thymic epithelial cells

Severe combined immune deficiency (SCID) includes various inherited immune disorders characterized by severe lymphopenia and lack of adaptive immunity. Over the past decade, allogeneic hematopoietic stem cell transplantation (HSCT) and gene correction of autologous stem cell precursors have achieved substantial success in treating patients with SCID thanks to newborn screening and improvement in donor selection, transplant protocols, and critical care.

For patients with SCID, the use of preparative regimens aimed at facilitating the engraftment of donor-derived hematopoietic stem cells (HSCs) continues to be controversial because T-cell reconstitution from a pool of committed lymphoid progenitors is also observed in the absence of durable HSC engraftment. Without conditioning, however, a higher risk of graft rejection and poor T- and B-cell reconstitution have been reported for patients with recombinase-activating gene (RAG) mutations, especially after haploidentical HSCT. In addition to natural killer cell–mediated rejection of donor cells, it has been hypothesized that poor immune reconstitution may also reflect competition between autologous and donor cells at early stages of T- and B-cell development that precede expression of the RAG genes. It has been demonstrated that the use of preparative regimens for HSCT in RAG-deficient patients is associated with a lower risk of treatment failure and superior T- and B-cell reconstitution than is observed even in a RAG1-deficient patient with immune dysregulation. However, conditioning regimens may cause acute and chronic toxicity, including organ damage, risk of infection, and infertility. These considerations are particularly important for RAG deficiency manifesting as combined immunodeficiency with immune dysregulation (CID-ID), in which the unusual clinical presentation often leads to delayed diagnosis and progressive development of organ damage. In these patients, the mortality rate reported after HSCT is higher than the rate observed in patients with typical or atypical SCID. Overall, these observations emphasize the need to develop nongenotoxic conditioning regimens. Recently, biologic approaches based on mAbs specifically targeting hematopoietic stem and progenitor cells (HSPCs) have been developed. The use of anti-CD117 mAb has been shown to efficiently condition immunocompetent mice, enabling the engraftment of donor cells, and a clinical trial is under way in patients with SCID (ClinicalTrials.gov identifier NCT02963064). However, although CD117-SAP represents a promising nonmyeloablative agent as it depletes autologous HSPCs while preserving host immunity, its use may not suffice in the context of CID-ID, in which there is a specific need to eliminate autoreactive host cells. For this reason, because of their ability to eliminate both precursor and mature hematopoietic cells (as they all express CD45), anti-CD45 mAbs represent a more attractive target for the conditioning of patients with CID-ID. Indeed, lytic anti-CD45 mAbs have been tested in patients with hematologic malignancies, and promising results have been observed even in a RAG1-deficient patient with immune dysregulation. Conjugation of anti-CD45 mAb with saporin, a ribosome-inactivating protein that lacks the cell entry domain and is toxic only on receptor-mediated internalization, results in an immunotoxin (anti-CD45 mAb conjugated with saporin [CD45-SAP]) that efficiently depletes HSCs in wide-type (WT) mice, enabling stable multilineage engraftment with minimal organ toxicity. However, it is not known whether these innovative immunotoxin-based conditionings are effective in immunodeficient models in which bone marrow (BM) and thymus niches are occupied by autologous mutant T- and B-progenitor cells.
This is of special concern for patients whose hypomorphic mutations cause both immunodeficiency and severe immune dysregulation. Murine models recapitulating the spectrum of phenotypes associated with RAG mutations in humans may represent a useful tool to test such novel therapeutic approaches. We have recently described newly generated mouse models carrying missense mutations in the RAG1 carboxy-terminal domain, permitting partial T- and B-cell development and recapitulating the phenotype observed in patients with CID-ID. Here we report the effect of T- and B-cell development and recapitulating the phenotype described by newly generated mouse models carrying missense mutant mice, mimicking SCID, and the Rag1-mutant mice carrying a homozygous F971L mutation (Rag1-F971L), recapitulating CID-ID.

METHODS

Mice

C57Bl/6 WT mice were purchased from Charles River Laboratories, Inc (Calco, Italy, and Wilmington, Mass). B6.129S7-Rag1F971L/m (referred to as Rag1-KO), purchased from The Jackson Laboratory, were maintained in specific pathogen–free conditions, with experimental procedures approved by the institutional animal care and use committee of San Raffaele Hospital (protocol 910). Rag1F971L/F971L (referred to as Rag1-F971L) mice were studied according to protocol ASP LCM6E, which was approved by the National Institute of Allergy and Infectious Diseases animal care and use committee.

Conditioning and transplantation protocols

Lineage-negative (Lin−) cells were isolated as described26 from 6- to 10-week-old donor CD45.1 WT mice and intravenously administered at a dose of 0.5 × 10^6 cells on the day of transplantation (day 0). Lin− cell purity (>90%) was assessed by flow cytometry. The CD45-SAP immunotoxin was prepared as described27 by combining a biotinylated anti-CD45.2 antibody (clone 104, Biologend, San Diego, Calif) with streptavidin-SAP conjugate (Advanced Targeting Systems, San Diego, Calif) in a 1:1 molar ratio. Groups of CD45.2 Rag1-KO and Rag1-F971L recipient mice were conditioned by using the following regimens: (1) lethal (8-Gy) TBI at day −1, (2) low-dose TBI (2 Gy) at day −1, (3) intravenous injection of CD45-SAP (3 mg/kg) at day −8, and (4) CD45-SAP (3 mg/kg) at day −8 and 2 Gy of TBI at day −1. The mice were followed until 16 weeks or 21 weeks after transplantation and then humanely killed. The levels of the liver enzymes alanine aminotransferase and aspartate aminotransferase were measured as described in the Methods section of the Online Repository (at www.jacionline.org).

In vivo immunization and antibody response

In vivo challenge with the T-dependent antigen 2,4,6-trinitrophenyl (TNP)-conjugated keyhole limpet hemocyanin was performed 4 months after transplantation as previously described.26 TNP-specific antibody titers were measured by using a multiplex assay (Beadlyte Mouse Immunglobulin Isotyping kit [Millipore, Burlington, Mass]) on a Luminex Magpix instrument (Luminex Corp, Austin, Tex). Serum IgG autoantibodies were measured by using a microarray platform as described in the Methods section of the Online Repository.

Flow cytometry and TEC isolation

Single-cell suspensions were obtained from BM, spleen, thymus, and peripheral blood (PB) and stained with mAbs listed in Table E1. Samples were acquired on a FACSCanto II system (BD Biosciences, San Jose, Calif). Thymic epithelial cells (TECs) were isolated as previously described27 and analyzed as described in the Methods section of the Online Repository.

RESULTS

Conditioning is required in null and hypomorphic Rag1 mice

HSCT without conditioning in RAG-deficient patients is associated with poor immune reconstitution, possibly reflecting competition between autologous and donor-derived stem and lymphoid progenitor cells.27 To assess whether the BM niches of Rag1-null and Rag1-F971L mice are receptive to donor stem cell engraftment in the absence of depletion of autologous HSPCs, we transplanted BM Lin− cells from C57Bl/6 CD45.1 WT mice into unconditioned C57Bl/6 CD45.2 Rag1-KO and Rag1-F971L mice. The proportions of donor-derived CD11b+ myeloid cells in the PB (Fig 1, A) and Lin− Sca1+ c-kit+ (LSK) CD48− CD150− HSCs in the BM (Fig 1, B) were very low (<5%) in all Rag1-mutant recipient mice after the transplant procedure. To verify whether these low proportions of donor cell engraftment could nonetheless permit immune reconstitution, we analyzed the immune cell composition in central and peripheral lymphoid organs. Rag1-mutant mice treated by unconditioned HSCT did not reverse the B- and T-cell differentiation blocks in the BM (Fig 1, C) and thymus (Fig 1, D), respectively. In particular, the distribution of B-cell subsets in unconditioned mice was superimposable to the pattern observed in untreated Rag1-mutant mice, with a significant increase in the proportion of B220low CD43− IgM− pre-B cells as compared with what was observed in WT mice (Fig 1, C [left panel]). Furthermore, in both models the absolute count of immature B cells remained significantly lower than in WT mice (Fig 1, C [right panel]). Thymopoiesis remained blocked at the CD4+ CD8− double-negative (DN) stage in Rag1-KO mice on unconditioned transplantation (Fig 1, D). Untreated Rag1-F971L mice showed residual capacity to generate double-positive and single-positive (SP) cells (Fig 1, D [left panel]), and only a modest increase in their proportion was observed after unconditioned HSCT (Fig 1, D).

The peripheral reconstitution mirrored that observed in central organs, with low white blood cell (WBC) counts measured over time in the PB of both Rag1-mutant strains on unconditioned HSCT (Fig 1, E). Four months after unconditioned transplantation, the absolute number of CD19+ B220+ B cells in the spleen of Rag1-mutant mice was no different from the values observed in untreated mice, but it was significantly lower than in WT mice (Fig 1, F). Moreover, flow cytometric analysis of splenic B-cell subsets showed that unconditioned HSCT did not induce amelioration in the distribution of transitional (CD19+ B220+...
FIG 1. Myeloid chimerism and immunologic reconstitution in unconditioned Rag1\textsuperscript{mut} mice. A, Kinetics of myeloid chimerism measured by flow cytometry as the proportion of donor WT CD45.1\textsuperscript{+} cells gated on CD11\textsuperscript{b}\textsuperscript{+} cells in the peripheral blood at different time points after the transplant (post-Tx) in unconditioned (nc) Rag1-KO (knockout [KO]) mice (n = 6) and Rag1-F971L (F971L) mice (n = 5-9). B, Donor chimerism in HSCs identified as LSK CD150\textsuperscript{+} CD48\textsuperscript{--} double-negative (DN), CD4\textsuperscript{+} CD8\textsuperscript{--}, and SP8 (CD4\textsuperscript{--}CD8\textsuperscript{--}) cells of Lin\textsuperscript{--} cells isolated from BM cells 16 weeks after the transplant. C, B-cell developmental stages were analyzed by flow cytometry and shown as proportion of thymocytes (left panel) and absolute counts (right panel) of B cells in BM (WT [n = 23], KO ut [n = 9], KO nc [n = 6], F971L ut [n = 5], and F971L nc [n = 8]) mice). One-way ANOVA, Kruskal-Wallis test on pre–B-cell frequencies (left panel) and immature B-cell counts (right panel), CD4\textsuperscript{+} CD8\textsuperscript{--} double-negative (DN), CD4\textsuperscript{+}CD8\textsuperscript{--} double-positive, SP4 (CD4\textsuperscript{+}CD8\textsuperscript{+}), and SP8 (CD4\textsuperscript{+}CD8\textsuperscript{+}) cells were analyzed by flow cytometry and shown as proportion of thymocytes (left panel) and absolute counts (right panel) (WT [n = 20], KO ut [n = 7], KO nc [n = 6], F971L ut [n = 6], and F971L nc [n = 8]) mice). One-way ANOVA, Kruskal-Wallis test on DN cell frequencies (left panel) and double-positive (DP) cell counts (right panel). D, WBCs were measured over time in the PB. One-way ANOVA, Kruskal-Wallis test at 12 weeks after the transplant. Asterisk colors indicate the groups of comparison. F, Splenic B-cell counts are shown in the graph. G, Proportions of splenic transitional (Trans), follicular (FO), and MZ B cells were analyzed by flow cytometry. One-way ANOVA, Kruskal-Wallis test on FO B-cell frequencies. H, Splenic T-cell counts are shown in the graph. I and J, Phenotypic analysis results of splenic T lymphocytes are shown in the graph according to the expression of CD44 on the CD3\textsuperscript{+} cells (I) and CD3\textsuperscript{+}CD8\textsuperscript{+} cells (J); 1-way ANOVA, Kruskal-Wallis test on naive T cells. F and H, Gray dots in WT bar were values from the SR-Tiget laboratory, and pink dots indicate values from the National Institutes of Health laboratory; 1-way ANOVA, Kruskal-Wallis test for multiple comparison. *P < .05; **P < .005; ***P < .0005; ****P < .0001. Means ± SDs are shown. Eff/mem, Effector/memory.
CD21<sup>intermediate/low</sup> CD24<sup>high</sup>, follicular (CD19<sup>+</sup> B220<sup>+</sup> CD21<sup>intermediate</sup> CD24<sup>low</sup>), and marginal zone (MZ) (CD19<sup>+</sup> B220<sup>+</sup> CD21<sup>high</sup> CD24<sup>intermediate</sup>) B cells (Fig 1, G). Similarly, the T-cell counts remained 50- to 100-fold lower in mouse models both with and without transplantation than in untreated WT mice (Fig 1, H). Phenotypic analysis of splenic T-cell subsets did not reveal any difference in the proportion of naive (CD45R0<sup+</sup>) and effector/memory (CD62L<sup>−</sup> CD44<sup+</sup>) CD4<sup+</sup> (Fig 1, J) and CD8<sup+</sup> (Fig 1, J) cells between untreated and unconditioned Rag1<sup+</sup> mutant mice that received transplants.

Altogether, these data demonstrate that in the absence of conditioning, MHC-matched HSCT into Rag1-deficient hosts does not enable effective engraftment of donor-derived hematopoietic and progenitor cells and does not correct the immune deficiency, indicating the need to deplete HSPCs.

**CD45-SAP induces efficient depletion of endogenous HSCs in Rag1<sup+</sup>mutant mice**

To test whether conditioning with CD45-SAP can efficiently deplete endogenous HSPCs from the BM and thymus, we injected Rag1<sup+</sup>-mutant mice with the CD45-SAP immunotoxin, alone or in combination with low-dose (2-Gy) TBI, and compared the results with those obtained with 2 Gy or 8 Gy of TBI. CD45-SAP–based conditioning regimens were well tolerated in both Rag1<sup+</sup>-mutant mice (see Fig E1, A in the Online Repository at www.jacionline.org). After they had been humanely killed, necropsy did not show macroscopic alterations in their organs; in addition, normal serum levels of aminotransferase enzymes were observed in the majority of treated Rag1-deficient mice. Only a few mice showed a modest increase in alanine aminotransferase and aspartate aminotransferase levels, suggesting mild liver toxicity on conditioning with CD45-SAP (see Fig E1, B and C). To assess the degree of HSC depletion, we evaluated the absolute counts of LSK cells (which comprise both HSCs and progenitor cells) and LSK CD45<sup+</sup> CD150<sup+</sup> HSCs in the BM of Rag1<sup+</sup>-mutant mice 8 days after CD45-SAP administration or 1 day after irradiation (see Fig E2, A in the Online Repository at www.jacionline.org). A single dose of CD45-SAP immunotoxin resulted in the depletion of 85.9% and 76.3% of LSK cells in Rag1-KO and Rag1-F971L mice, respectively (Fig E, 2B). Even higher levels of depletion were observed in the HSC compartment (95.2% in Rag1-KO and 91.7% in Rag1-F971L mice) (see Fig E2, C). Use of low-dose TBI was associated with significant variability in the depletion of HSCs in both models (see Fig E2, C). Of note, the combination of CD45-SAP with 2 Gy of TBI displayed a synergistic effect in depleting HSCs (94.7% in Rag1-KO and 100% in Rag1-F971L mice) and progenitor cells (96.3% in Rag1-KO and 99.9% in Rag1-F971L mice) (see Fig E2, B and C) and corresponded to the highest level of depletion in both mouse models.

The kinetics of immune recovery in mice conditioned with CD45-SAP mirror donor chimerism in PB

To determine whether the degree of HSC depletion induced by CD45-SAP permits durable multilineage engraftment, we monitored the kinetics of myeloid chimerism and immune reconstitution in the PB over time by flow cytometry. As expected, low levels of myeloid chimerism were observed in both Rag1<sup+</sup>-mutant models on conditioning with 2 Gy of TBI, whereas 8 Gy of TBI induced the highest levels of myeloid engraftment (see Fig E2, D and E). Conditioning with CD45-SAP alone allowed intermediate levels of myeloid chimerism in both models, but the combination of CD45-SAP and 2 Gy of TBI yielded similarly high levels of donor myeloid chimerism, as observed in 8-Gy–conditioned mice, suggesting optimal engraftment of donor-derived long-term HSCs (see Fig E2, D and E).

In parallel, we monitored the kinetics of immune reconstitution in the PB (see Fig E3, A in the Online Repository at www.jacionline.org). Irradiation with 2 Gy alone was not sufficient to normalize the WBC count or correct T- and B-cell deficiency in Rag1<sup+</sup>-mutant mice (see Fig E3, B–E). In contrast, Rag1<sup+</sup>-mutant mice that received a transplant and were conditioned with CD45-SAP plus 2 Gy of TBI or with 8 Gy showed a significant increase in WBC, T-cell, and B-cell counts already at 8 weeks after transplantation (see Fig E3, B–D). Conditioning with CD45-SAP alone resulted in slower kinetics of WBCs and lymphoid recovery, with B-cell reconstitution in particular remaining suboptimal in both mouse models (see Fig E3, B–E).

These results indicate that conditioning with CD45-SAP plus 2 Gy of TBI promotes high levels of engraftment of donor HSPCs equivalent to what was observed with 8 Gy of TBI, and it permits a faster kinetics of immune reconstitution than either CD45-SAP or 2 Gy of irradiation alone.

**CD45-SAP–based conditioning allows efficient donor chimerism and lymphopoiesis in central lymphoid organs of Rag1<sup+</sup>mutant mice**

To verify whether conditioning with CD45-SAP is able to create a permissive environment for stable engraftment of donor HSCs in Rag1<sup+</sup>-mutant mice, we analyzed the proportion of donor CD45.1<sup+</sup> HSCs in the BM of differentially conditioned Rag1<sup+</sup>-mutant mice 4 months after transplantation. High levels of donor chimerism were observed in the HSC compartment of mice conditioned with 8 Gy or CD45-SAP plus 2 Gy, irrespective of the genetic background (Fig 2, A). Administration of CD45-SAP alone resulted in a partial and variable donor HSC chimerism ranging from 32.04% to 100% in Rag1-KO mice and from 5.02% to 86.2% in Rag1-F971L mutants. In contrast, 2 Gy of irradiation resulted in poor HSC engraftment in both models (Fig 2, A).

To test how conditioning affects B-cell reconstitution, we determined the proportion of donor CD45.1<sup+</sup> WT cells at various stages of differentiation. Consistent with the levels of donor HSC chimerism, conditioning with 2 Gy of irradiation and with CD45-SAP resulted in modest or intermediate levels of donor chimerism, respectively, at the pro–B-cell stage, in which competition with autologous cells occurs (Fig 2, B). In contrast, conditioning with CD45-SAP plus 2 Gy or with 8 Gy of irradiation allowed high levels of donor chimerism already at the pro–B-cell stage. Finally, irrespective of the nature of conditioning, robust donor chimerism was detected at later stages of B-cell development, and even in Rag1-F971L mice, in spite of the residual capacity to generate mature B cells<sup>23</sup> (Fig 2, C). Immunotoxin-based regimens or 8 Gy of TBI resulted in a distribution of BM B-cell subsets that was similar to what was observed in WT mice (Fig 2, C [left panel]), with an absolute count of immature and recirculating mature B
cells that was significantly higher than in untreated Rag1-KO and Rag1-F971L mice (Fig 2, C [right panel]).

In parallel, we assessed donor chimerism in the thymus at different stages of T-cell development, including early thymic progenitors, DN1 to DN4 stage cells, double-positive cells, and SP4 (CD4+CD8−) and SP8 (CD4−CD8+) cells. Interestingly, in both mouse models, conditioning with CD45-SAP alone or with 2 Gy was associated with a fluctuation in the proportion of donor cells at early stages (DN1-4) of thymopoiesis, and low levels of donor chimerism were observed especially at the DN2-DN3 stage (Fig 3, A). In contrast, conditioning with CD45-SAP plus 2 Gy or with 8 Gy permitted robust levels of donor chimerism throughout the early stages of thymopoiesis (Fig 3, A). Finally, irrespective of the conditioning used, high levels of donor chimerism were detected beyond the DN3 stage, reflecting the selective advantage provided by normal Rag1 expression to bypass the developmental block. To better quantify the impact of conditioning and transplant on thymic output, we analyzed thymocyte counts and subset distribution when the mice were humanely killed. Both untreated Rag1-mutant models were characterized by a dramatic reduction in total thymocyte counts (Fig 3, B). Thymic output was corrected in

![Image of Figure 2](https://example.com/image2.png)

**FIG 2.** Donor chimerism and immunologic reconstitution in the BM of conditioned Rag1mut mice. **A,** Donor chimerism in HSCs was measured by flow cytometry in Lin− cells isolated from Rag1-KO (knockout [KO]) and Rag1-F971L (F971L) mice and shown as the proportion of donor CD45.1+ cells and recipient CD45.2+ cells in an LSK CD150+CD48− cell gate. One-way ANOVA, Kruskal-Wallis test for multiple comparison. **B,** The proportion of CD45.1+ donor WT cells was evaluated in the main stages of B-cell development in the BM of Rag1-KO (top panel) and Rag1-F971L (bottom panel) mice. One-way ANOVA, Kruskal-Wallis test on pre–B-cell frequencies. Asterisk colors indicate the groups of comparison. **C,** The B-cell developmental stages were analyzed by flow cytometry and shown as proportion (left panel) and absolute counts (right panel) of B cells in the BM. One-way ANOVA, Kruskal-Wallis test on pre–B-cell frequencies (left panel) and immature B-cell counts (right panel). A-C, Analyses were performed 16 weeks after the transplant. *P < .05; **P < .005; ***P < .0005; ****P < .0001. Means ± SDs are shown. mat. rec., Mature recirculating; ut, untreated.
the mice conditioned with CD45-SAP alone or in combination with 2 Gy and with 8 Gy of irradiation (Fig 3, B), with rescue of early and late thymopoiesis (Fig 3, C) in both mouse models. Conversely, 2 Gy of TBI only partially restored thymocyte counts (Fig 3, B) and T-cell subset distribution (Fig 3, C) in both mouse models.

**CD45-SAP conditioning supports the reconstitution of epithelial cells in the thymus of Rag1-mutant mice**

To test the effect of conditioning on thymic epithelial architecture, whole thymic structures were analyzed by histology, and in parallel the proportions of medullary TECs and cortical TECs were assessed by flow cytometry. Conditioning with CD45-SAP–based regimens allowed restoration of normal thymus morphology with clear demarcation of medullary and cortical areas and normalization of the medullary-to-cortical ratio (Fig 4, A and B in the Online Repository at www.jacionline.org). Conversely, poor reconstitution of the thymic epithelial compartment was observed in Rag1-mutant mice conditioned with 2 Gy of irradiation alone (Fig 4, A and B). Flow cytometric analysis further demonstrated that in Rag1-KO mice CD45-SAP–based regimens were more effective than irradiation-only–based regimens in increasing the frequency of mTECs (Fig 4, C). Overall, reconstitution of the mTEC compartment was more robust in Rag1-F971L than in Rag1-KO mice, irrespective of the conditioning used (Fig 4, C).

Altogether, these findings indicate that conditioning with CD45-SAP, alone or in combination with 2 Gy of TBI, permits reconstitution of both thymocyte and TEC compartments.

**Correction of peripheral lymphoid organ abnormalities in Rag1-mutant mice on conditioning with CD45-SAP–based regimens**

Next, we assessed the immunologic reconstitution by analyzing the T- and B-cell compartment in the spleen of Rag1-mutant mice 4 months after transplantation. As expected, because of the strong selective advantage of WT-derived cells in
generating mature T and B lymphocytes, the splenic T- and B-cell
compartments of Rag1-KO mice that had received a transplant
were composed entirely of CD45.1 donor-derived cells in all
conditioning groups (Fig 5, A). In Rag1-F971L mice, a small pro-
portion of host-derived T and B cells was observed on condition-
ing with CD45-SAP alone, with CD45-SAP plus 2 Gy, or with 2
Gy (Fig 5, A). The levels of myeloid engraftment in the spleen
paralleled those found in the PB (see Fig E2, D and E) and in
HSCs (see Fig E2, C).

In both Rag1-mutant models, irrespective of the conditioning
used, transplantation resulted in an increase in the splenic T-cell
counts, as compared with in untreated mice, although the total
T-cell count remained lower than in WT mice (Fig 5, B). To
exclude the possibility that the increase of T-cell counts after
transplantation may reflect homeostatic proliferation in a T-cell
lymphopenic environment, we evaluated the distribution of naive
and effector/memory T cells. As previously demonstrated,24
hypomorphic Rag1-F971L mice have a significant decrease in
the proportion of naive T cells (Fig 5, C) as compared with that
in WT mice and a relative increase in the proportion of effector/memory T cells (Fig 5, C). After transplantation, a
similar distribution of naive and effector/memory CD4+ and
CD8+ cells was observed in both Rag1-mutant models as
compared with in WT mice, with the exception of Rag1-KO
mice conditioned with low-dose irradiation (Fig 5, C). Similarly,
improved B-cell reconstitution was observed in both models
as compared with that in their respective untreated controls,
although in all conditions B-cell count was lower than in WT
mice (Fig 5, D). In both models, the relative distribution of trans-
itional, follicular, and MZ B cells approached what was observed
in WT mice, in particular, in mice conditioned with CD45-SAP–
based regimens or with 8 Gy of TBI (Fig 5, E). In contrast, 2 Gy of
TBI was associated with a poorer B-cell count, a relative excess of
MZ B cells, and a lower proportion of follicular B cells, especially
in Rag1-KO mice (Fig 5, D and E).

Conditioning with CD45-SAP allows correction of
adaptive immune responses in Rag1-mutant mice that received a transplant
Rag1-KO and Rag1-F971L mice are characterized by lack
and variable levels of serum immunoglobulins,
Compared with untreated mice, the Rag1-KO mice that received a transplant had significantly higher IgM and IgG serum levels that were within the normal range or higher (Fig 6, A and B). Untreated Rag1-F971L mice had normal IgA serum levels observed in both Rag1-

分别。^{24,25} 相比未治疗的小鼠，Rag1-KO小鼠接受移植后IgM和IgG血清水平显著高于正常范围甚至更高（Fig 6，A和B）。未治疗的Rag1-F971L小鼠的正常IgA血清水平在 WT小鼠中均被观察到。
mutant models after transplantation with use of CD45-SAP–based regimens, whereas somewhat lower levels were detected in mice conditioned with 2 Gy of irradiation (Fig 6, C). To evaluate how conditioning regimens may affect the quality of humoral immune responses after transplantation, WT and Rag1-mutant mice were immunized with the T-cell–dependent TNP-conjugated keyhole limpet hemocyanin antigen. Compared with untreated controls, most Rag1-mutant mice that received a transplant were able to produce specific antibodies, with the greatest responses being observed in CD45-SAP plus 2 Gy– and 8 Gy–treated Rag1-KO mice and in CD45-SAP– and 8 Gy–treated Rag1-F971L mice (Fig 6, D). Of note, levels of circulating autoantibodies, which are elevated in Rag1-F971L mice as a sign of tolerance breakdown,24 were markedly reduced in CD45-SAP–conditioned mice and even normalized in mice conditioned with CD45-SAP plus 2 Gy of irradiation, or with 8 Gy of irradiation (see Fig E4 in the Online Repository at www.jacionline.org).

**DISCUSSION**

Herein, we have presented preclinical data supporting the use of a nongenotoxic, immunotoxin-based conditioning regimen for HSCT of patients with either severe or hypomorphic forms of RAG deficiency. We first demonstrated that in the absence of conditioning, host competition dramatically limits donor HSC engraftment, even in an MHC syngeneic setting, indicating that HSC depletion is required to allow donor cell engraftment and long-term immunologic reconstitution, irrespective of the severity of the immunologic phenotype. These findings are consistent with clinical observations. In particular, Schuetz et al have shown that unconditioned HSCT from matched sibling...
donors for *RAG* deficiency is associated with T-cell counts in the lower range of normal, and more variable and often incomplete, B-cell reconstitution. Moreover, it has been demonstrated that *RAG* deficiency and lack of chemotherapy-based conditioning represent risk factors for incomplete immune reconstitution after HSCT from donors other than HLA-matched siblings. Although a prospective clinical trial (ClinicalTrials.gov identifier NCT03619551) is currently under way to compare different doses of busulfan-based regimens for their capacity to induce immune reconstitution in newly diagnosed infants with SCID, alternative approaches, based on immunotoxins, are receiving increasing consideration, as they could help reduce the risks of acute and chronic toxicity associated with chemotherapy and TBI. In particular, promising results have been recently reported with use of antibody-drug conjugate (ADCs) for HSCT in both humanized mouse models and nonhuman primates, as well as for autologous gene therapy, and they are expected to translate soon into clinical trials. These observations will be instrumental to extend a nongenotoxic regimen to patients undergoing secondary HSCT transplant for loss of chimerism or insufficient thymic output.

Here, we have compared CD45-SAP immunotoxin with genotoxic TBI in terms of their capacity to permit donor stem cell engraftment and immune reconstitution in two mouse models of *RAG* deficiency: the *Rag1*-KO mouse, mimicking SCID, and the *Rag1-F971L* mouse, modeling CID-ID. A single dose of CD45-SAP immunotoxin resulted in different kinetics of LSK depletion in the 2 mouse models. Both in the BM and in the thymus, conditioning with 2 Gy of TBI or with CD45-SAP alone resulted in low and intermediate levels of engraftment, respectively, at pro-/pre-B and DN3 stages, in which competition from endogenous mutant cells is expected. In contrast, combining CD45-SAP with 2 Gy of TBI had a synergistic effect, leading to more robust donor engraftment and faster kinetics of immune reconstitution in both models, similar to what was observed with use of 8 Gy of TBI. We also showed that CD45-SAP–based regimens allow significant improvement of thymic architecture and maturation of TECs, which support thymopoiesis and mediate positive and negative selection. We had previously shown that abnormalities of thymic architecture and TEC composition in humans and mice with *RAG* defects are associated with molecular signatures of self-reactivity in the peripheral T-cell repertoire. Restoration of TEC maturation may therefore also have important implications for correction of the immune dysregulation that is often associated with *RAG* deficiency. Finally, conditioning of *Rag1-F971L* mice with CD45-SAP led to marked improvement of the autoantibody profile, especially when combined with low-dose TBI, indicating that this approach allows high levels of multilineage chimerism and corrects breakdown of immune tolerance.

Besides CD45-SAP, other mAb-based regimens have also been explored as nongenotoxic conditioning regimens. In particular, a humanized anti-CD117 mAb, targeting HSPCs, is being explored as single-agent conditioning regimen in patients with SCID (ClinicalTrials.gov Identifier NCT02963064), and the safety and efficacy of CD117-SAP immunotoxin have been tested in preclinical studies. Although targeting CD117 may open BM niches and facilitate donor stem cell engraftment, this approach would not deplete more mature lymphoid cells, which may compete with donor-derived cells at later stages of T- and B-cell development. In RAG deficiency, such cells may express self-reactive specificities because of the inefficiency of negative selection and may therefore mediate immune dysregulation. Our data demonstrate that CD45-SAP can also efficiently deplete lymphoid progenitor cells and, to some degree, even more mature cells in peripheral lymphoid organs. Our data also confirm and extend previous observations demonstrating the safety of this approach. A previous study has shown that a single dose of 3 mg/kg of CD45-SAP is sufficient to allow robust and durable donor engraftment. In this study we have demonstrated that optimal results are achieved when combining CD45-SAP and 2 Gy of TBI. Although low-dose TBI is often used as part of conditioning regimens in humans also; nonetheless, it represents a matter of concern in infants and young children, especially in patients with genetic defects associated with increased cellular radiosensitivity. Alternative approaches, such as use of higher doses of CD45 ADCs or combination with other mAb-based conditioning agents, need to be explored and would be particularly valuable in the treatment of diseases associated with cellular radiosensitivity.

One of the limitations of CD45-SAP is its half-life, which may lead to targeting of donor-derived HSCs also if the transplantation is performed shortly after immunotoxin injection. Moreover, transient hepatotoxicity has been reported after injection of saporin alone, ADCs, or radiolabeled anti-CD45 antibody, and mild signs of liver damage have also been observed in a minority of animals included in the present study. Although recent data showed that ADCs have a safer toxicity profile than do conventional conditioning regimens based on alkylating agents and/or radiotherapy, several steps are needed before advancing this type of strategy into the clinical setting. In particular, future preclinical studies, may help assess the dosage, safety, and efficacy of other anti-CD45 ADCs (CD45 ADCs) with shorter half-life and similar or even superior HSC-depleting properties.

Finally, although our model has explored the feasibility and efficacy of CD45-SAP in a mouse model of syngeneic HSCT, it is possible that more complex conditioning regimen protocols combining CD45 ADCs with other mAbs targeting T and/or natural killer cells may be needed to attain robust and durable multilineage engraftment in MHC-matched nonsyngeneic and MHC-mismatched settings.

In summary, we have demonstrated that CD45-SAP is a potent immunotoxin that can efficiently deplete endogenous HSPCs and more mature lymphoid cells, allowing robust donor stem cell engraftment and immune reconstitution in mouse models of null and hypomorphic *Rag1* mutations. These results may pave the way for applying a similar strategy with novel CD45 ADC molecules as a conditioning regimen for HSCT or gene therapy not only in patients with RAG deficiency but also in patients with other inborn errors of immunity associated with immune dysregulation or with a higher risk of poor stem cell engraftment, reduced thymopoiesis, and premature loss of T-cell repertoire diversity after HSCT.

Clinical implications: Conditioning with anti-CD45 ADCs may represent a novel and safe conditioning regimen for patients with *RAG* deficiency and other inborn errors of immunity.

REFERENCES
1. Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 2014;371:434-46.
Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Pack JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 2014;133:1092-8.

Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Res 2019;2019:241-52.

Haddad EL, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prokop SE, et al. SCID genotype and 6-month post-transplant CD4 count predict survival and immune recovery: a PIDTC Retrospective Study. Blood 2018;132:1737-49.

Fischer A, Hacene-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med 2020;217.

Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. Hypomorph Rag1 mutations alter the preimmune repertoire at early stages of lymphoid development. Blood 2018;132:281-92.

Shaw P, Shizuru J, Hoenig M, Veys P, Iewp E. Conditioning perspectives for primary immunodeficiency Treatment Consortium experience. J Allergy Clin Immunol 2014;133:973-83.
METHODS

In vivo challenge

In vivo challenge with T-dependent antigen was performed 4 months after transplantation as previously described. Briefly, serum samples were collected immediately before intravenous immunization with 100 μg of TNP-conjugated keyhole limpet hemocyanin (Biosearch Technologies, Novato, Calif). A boosting dose of 100 μg of TNP-conjugated keyhole limpet hemocyanin was injected intraperitoneally 3 weeks later, and serum samples were collected 7 days later.

Flow cytometry and TEC isolation

Single-cell suspensions were obtained from BM, spleen, thymus, and PB and stained with the mAbs listed in Table E1 in the Online Repository (at www.jacionline.org). Streptavidin phycoerythrin (PE)–cyanine 7 (Cy7) (BD PharMingen, San Jose, Calif) was used for the detection of biotinylated antibody, and a Live/Dead Fixable Dead Cell Stain Kit (Thermo Fisher Scientific, Waltham, Mass) was added to the antibody mix to exclude dead cells by flow cytometry. Samples were acquired on a FACSCanto II system (BD Biosciences, San Jose, Calif).

TECs were isolated as previously described. Cleaned thymus was digested, and TECs were enriched by depleting CD45+ cells with anti-CD45 microbeads (Miltenyi Biotec, Cambridge, Mass) and immediately used for the staining with the following antibodies: anti-CD45 PE-Cy7 (clone 30-F11, BioLegend, San Diego, Calif), anti-EpCam peridinin chlorophyll protein–cyanine 5.5 (clone G8.8, BioLegend), anti-Ly51 PE (clone 6C3, Miltenyi Biotec), anti-MHC class II allophycocyanin-Cy7 (clone M5/114.15.2, BioLegend), and anti–Ulex europeaus agglutinin 1 (UEA1) (clone FL-1061, Vector Laboratories, Burlingame, Calif). mTECs were defined as EpCam+ UEA1low or EpCam+ UEA1high, and cortical TECs (cTECs) as EpCam+ Ly51– CD80lowCD86low or EpCam+ Ly51+ CD80high. A Live/Dead Fixable dead cell stain kit was used for assessing cell viability. Events were acquired on an LSR Fortessa flow cytometer (BD Biosciences, San Jose, Calif). All data were analyzed by using FlowJo software, version 10.5.2 (FlowJo, LLC, Ashland, Ore).

ELISA and autoantibody profile

Levels of IgG isotypes, IgM, and IgA were measured in plasma samples by multiplex assay (Beadlyte Mouse Immunoglobulin Isotyping kit, Millipore, Burlington, Mass) on a Luminex Magpix instrument (Luminex Corp, Austin, Tex). Anti-TNP specific antibody titers were measured by ELISA on serum samples after polystyrene plates were coated with 8 μg/mL of TNP(4)-BSA (Biosearch Technologies, United Kingdom). Serial dilutions of serum (from 1:100 to 1:72,900) were added, and the reaction was revealed using alkaline phosphatase–conjugated goat anti-mouse IgG (Sigma-Aldrich, Burlington, Mass), followed by addition of p-nitrophenylphosphate (Sigma-Aldrich). OD values were measured at 405 nm by using a Multiskan GO spectrophotometer (Thermo Fisher Scientific, Frederick, Md).

Protein arrays were used to screen for a broad panel of IgG autoantibodies. Protein arrays were used to screen for a broad panel of IgG autoantibodies. Autoantigen microarrays were manufactured, hybridized, and scanned by the Microarray Core Facility at the University of Texas Southwestern Medical Center (Dallas, Tex). Serum was collected from Rag1–F971L mice 16 weeks after transplantation and distinct conditioning regimens. Sera were also collected from WT and MRL mice, as negative and positive control groups, respectively.

Briefly, sera were incubated with an autoantigen array, and binding of autoantibodies was detected by using cyanine 3–labeled anti-IgG with a laser wavelength of 532 nm. As a quantitative measure of the ability to resolve true signal from background noise, we used the signal-to-noise ratio (SNR), which was calculated as follows: SNR = (Foreground median – Background median)/ SD (Background). SNR values equal or higher than 3 were considered representative of true signal. The net fluorescence intensity and net SNR for each antigen were calculated by subtracting all the negative control (PBS) effects that were included for each experiment as negative control. The antibody score was computed as follows: Antibody score = log2(NFI*SNR + 1), where NFI is the net fluorescence intensity. A heatmap was generated with R software based on log2 fold change in the antibody scores compared with the average for Rag1–F971L untreated mice.

Liver function

Alanine aminotransferase and aspartate aminotransferase levels were measured in plasma samples by using quantiLab alanine aminotransferase/glutamate pyruvate transaminase and aspartate aminotransferase/oxaloacetate transaminase kits and an Ilab Aries instrument (Werfen-Italia, Instrumentation Laboratory, Milan, Italy), according to the manufacturer’s instructions. All measures were preceded by the analysis of certified internal quality controls to verify the analytic performance of the test.

REFERENCE

E1. Cagno V, Castiello MC, Fontana E, et al. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. J Allergy Clin Immunol 2018;142:928-41.e928.
FIG E1. Survival rate of conditioned Rag1<sup>−/−</sup> mice. A, Kaplan-Meier survival curves for Rag1-KO (knockout [KO]) (left panel) and Rag1-F971L (F971L) (right panel) mice subjected to conditioning and transplantation. Rag1-KO mice were treated with the following: CD45-SAP (n = 16); CD45-SAP plus 2 Gy (n = 11); 8 Gy of irradiation (n = 13); and 2 Gy of irradiation (n = 11). Rag1-F971L mice were treated with the following: CD45-SAP (n = 11); CD45-SAP plus 2 Gy of irradiation (n = 11); 8 Gy of irradiation (n = 10); and 2 Gy of irradiation (n = 6). B and C, Liver function was analyzed by measuring alanine aminotransferase (ALT) (B) and aspartate aminotransferase (AST) (C) levels in plasma samples collected from Rag1-KO and Rag1-F971L mice undergoing various conditioning treatments when they were humanely killed (16 weeks after transplantation). Gray dots in the WT bar are values from samples collected at the SR-Tiget laboratory, and pink dots are values from samples collected at the National Institutes of Health laboratory. One-way ANOVA; Kruskal-Wallis test for multiple comparison; *P < .05; **P < .005; ***P < .0005; ****P < .0001. Means ± SDs are shown. ut, Untreated.
**FIG E2.** Depletion effect and engraftment level in conditioned Rag1mut mice. A, Time line and scheme of the experiment. B and C, Absolute counts of LSK (B) and HSC (C) cells at day 0 are shown as percentages of the mean value of the respective untreated Rag1-mutant group. One-way ANOVA, Kruskal-Wallis test for multiple comparison. D and E, Analysis of myeloid chimerism frequency over time after transplant (Tx) in the PB of Rag1-KO (KO) mice (D) and Rag1-F971L (F971L) (E). One-way ANOVA, Kruskal-Wallis test for multiple comparison at 16 weeks after transplant. Asterisk colors indicate the groups of comparison. The group treated with CD45-SAP included 11 KO mice and 10 F971L mice; the group treated with CD45-SAP plus 2 Gy of TBI included 7 KO mice and 6 F971L mice; and the group treated with 8 Gy of TBI included 12 KO mice and 10 F971L mice. *P < .05; **P < .005; ***P < .0005; ****P < .0001. Means ± SDs are shown.
FIG E3. Kinetics of the immunologic reconstitution over time in the PB of conditioned Rag1mut mice. A, Time line and scheme of the experiment. B-F, Analysis over time after transplant (Tx) WBC count (B), T-cell (CD3+) count (C), B-cell (CD19+ B220+) count (D), and myeloid cells (CD11b+) count (E) in the PB of Rag1-KO (knockout [KO]) (left panel) and Rag1-F971L (F971L) (right panel) mice. B-F, The group treated with CD45-SAP included 11 KO mice and 11 F971L mice; the group treated with CD45-SAP plus 2 Gy of TBI included 7 KO mice and 11 F971L mice; the group treated with 2 Gy of TBI included 11 KO mice and 7 F971L mice; and the group treated with 8 Gy of TBI included 11 KO mice and 10 F971L mice [WT control [ctrl] mice, n = 11-19 [left panels] and n = 8 [right panels]; KO ctrl mice, n = 11-16; and F971L ctrl mice, n = 7]. One-way ANOVA, Kruskal-Wallis test for multiple comparison at 16 weeks after transplantation. *P < .05; **P < .005; ***P < .0005; ****P < .0001. Means ± SDs are shown.
**FIG E4.** Autoantibody profile in *Rag1-F971L* mice subjected to conditioning and a transplant. Levels of IgG reactivity were tested against 123 antigens by autoantigen array in the sera of hypomorphic *Rag1-F971L* mice 16 weeks after transplant (post-Tx) and distinct conditioning regimens. The autoantibody profile of untreated WT, *Rag1-F971L*, and *MRL* mice are shown as control groups. Data are represented as a heatmap with colors corresponding to log2 fold change in antibody scores with the average for *Rag1-F971L* untreated mice.
### TABLE E1. List of antibodies

| Antibody          | Clone     | Source          | Identifier | Dilution |
|-------------------|-----------|-----------------|------------|----------|
| B220 APC-Cy7      | C363-16A  | BioLegend       | 103310     | 1:200    |
| B220 Pe-Cy7       | RA36B2    | BD Bioscience   | 552772     | 1:200    |
| CD3 APC-Cy7       | 145-2C11  | BD Bioscience   | 557596     | 1:100    |
| CD4 Pacific Blue  | GK1.5     | BioLegend       | 100428     | 1:500    |
| CD4 PerCP         | RM/4-5    | BD Bioscience   | 553052     | 1:500    |
| CD8 APC           | 53-6.7    | BioLegend       | 100712     | 1:400    |
| CD8 Pe-Cy7        | 53-6.7    | BD Bioscience   | 552877     | 1:400    |
| CD8 Pacific Blue  | 53-6.7    | BD Bioscience   | 558106     | 1:500    |
| CD11b Pacific Blue| M1/70     | BioLegend       | 101224     | 1:100    |
| CD19 PE           | 1D3       | BD Bioscience   | 553786     | 1:200    |
| CD19 eFluor450    | 1D3       | Thermo Fisher   | 48-0193-82 | 1:200    |
| CD21 APC          | 7E9       | BioLegend       | 123412     | 1:400    |
| CD24 PE           | M1/69     | BD Bioscience   | 553262     | 1:400    |
| CD25 PE           | PC61      | BioLegend       | 102008     | 1:200    |
| CD25 APC          | PC61      | BD Bioscience   | 557192     | 1:100    |
| CD43 biotinylated | S7        | BD Bioscience   | 553269     | 1:100    |
| CD44 FITC         | IM7       | BioLegend       | 103006     | 1:200    |
| CD45.1 FITC       | A20       | BD Bioscience   | 553775     | 1:200    |
| CD45.1 PE         | A20       | BD Bioscience   | 553776     | 1:200    |
| CD45.1 APC-Cy7    | A20       | BD Bioscience   | 560579     | 1:200    |
| CD45.1 Pacific Blue| A20      | BioLegend       | 110722     | 1:200    |
| CD45.2 PerCP5.5   | 104       | BD Bioscience   | 552950     | 1:200    |
| CD45.2 Pacific Blue| 104      | BioLegend       | 109820     | 1:200    |
| CD48 PE           | HM48-1    | BioLegend       | 103405     | 1:100    |
| CD62L APC         | MEL-14    | BD Bioscience   | 553152     | 1:200    |
| CD150 APC         | TC15-12F12.2 | BioLegend    | 115910     | 1:100    |
| cKit APC-Cy7      | 2BS       | BioLegend       | 105826     | 1:100    |
| IgM FITC          | II/41     | BD Bioscience   | 553437     | 1:200    |
| Mouse lineage cocktail | 17A2/RB6-8C5/6B2/  | BioLegend   | 133310     | 1:20    |
| Sca1 Pe-Cy7       | D7        | BioLegend       | 108114     | 1:100    |

*APC*, Allophycocyanin; *FITC*, fluorescein isothiocyanate; *PerCP*, peridinin chlorophyll protein.